Advertisement
Screener

United Therapeutics Corporation (UTHR) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

2.8 / 5 stars · 68/120 Roast Me

United Therapeutics Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-06-30 was 73.44K shares, a 78.76% decline year-over-year.
  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-03-31 was 81.11K shares, a 67.79% decline year-over-year.
  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-12-31 was 177.83K shares, a 37.51% decline year-over-year.
  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-09-30 was 210.26K shares, a 54.35% decline year-over-year.
  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 747.49K shares, a 84.32% increase from fiscal 2021.
  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 405.54K shares, a 13.11% decline from fiscal 2020.
  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 466.73K shares, a 143.71% increase from fiscal 2019.
  • United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 191.51K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month
2022-12-31747.49K shares
10-K · filed 2023-02-22
2021-12-31405.54K shares
10-K · filed 2023-02-22
2020-12-31466.73K shares
10-K · filed 2023-02-22
2019-12-31191.51K shares
10-K · filed 2022-02-24
2016-06-3073.44K shares
10-Q · filed 2016-07-28
542.63K shares
derived: sum of 4 quarters · filed 2016-07-28
2016-03-3181.11K shares
10-Q · filed 2016-04-28
814.85K shares
derived: sum of 4 quarters · filed 2016-07-28
2015-12-31177.83K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
985.58K shares
10-K · filed 2016-02-25
2015-09-30210.26K shares
10-Q · filed 2015-10-27
1.09M shares
derived: sum of 4 quarters · filed 2016-07-28
2015-06-30345.66K shares
10-Q · filed 2016-07-28
1.34M shares
derived: sum of 4 quarters · filed 2016-07-28
2015-03-31251.84K shares
10-Q · filed 2016-04-28
1.44M shares
derived: sum of 4 quarters · filed 2016-04-28
2014-12-31284.57K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
1.46M shares
10-K · filed 2016-02-25
2014-09-30460.60K shares
10-Q · filed 2015-10-27
1.39M shares
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30445.95K shares
10-Q · filed 2015-07-28
1.24M shares
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31271.24K shares
10-Q · filed 2015-04-28
997.99K shares
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31210.75K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
876.12K shares
10-K · filed 2016-02-25
2013-09-30310.67K shares
10-Q · filed 2014-10-28
854.79K shares
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30205.32K shares
10-Q · filed 2014-07-29
790.52K shares
derived: sum of 4 quarters · filed 2015-02-24
2013-03-31149.37K shares
10-Q · filed 2014-04-29
652.40K shares
derived: sum of 4 quarters · filed 2015-02-24
2012-12-31189.43K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
575.94K shares
10-K · filed 2015-02-24
2012-09-30246.40K shares
10-Q · filed 2013-10-29
403.63K shares
derived: sum of 4 quarters · filed 2014-02-25
2012-06-3067.20K shares
10-Q · filed 2013-07-25
177.37K shares
derived: sum of 4 quarters · filed 2014-02-25
2012-03-3172.92K shares
10-Q · filed 2013-04-25
433.93K shares
derived: sum of 4 quarters · filed 2014-02-25
2011-12-3117.12K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
837.69K shares
10-K · filed 2014-02-25
2011-09-3020.14K shares
10-Q · filed 2012-11-01
2011-06-30323.76K shares
10-Q · filed 2012-07-26
2011-03-31476.68K shares
10-Q · filed 2012-04-26
2010-12-313.34M shares
10-K · filed 2013-02-26
2009-12-31955.94K shares
10-K · filed 2012-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viatris Inc (VTRS)United States$20.008B-0.00
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17